Table 3. Relapse rate (R), disease-free (DFS) and overall survival (OS) according to the detection of the CK-19 mRNA (+) CTCs before and after the completion of adjuvant chemotherapy and the type of chemotherapy.
| |
CK-19 pre(−)/post(−) (n=252) |
CK-19 pre(−)/post(+) (n=56) |
CK-19 pre(+)/post(−) (n=103) |
CK-19 pre(+)/post(+) (n=134) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | R (%) | DFI (months) | OS (months) | R (%) | DFI (months) | OS (months) | R (%) | DFI (months) | OS (months) | R (%) | DFI (months) | OS (months) |
| Taxane-free |
21.4 |
121 |
134 |
40.0 |
105 |
127 |
34.5 |
105 |
122 |
50.6 |
86 |
110 |
| Taxane-based |
11.4 |
124 |
130 |
16.7 |
107 |
118 |
13.5 |
106 |
119 |
20.7 |
101 |
104 |
| P-value | 0.035 | 0.569 | 0.602 | 0.105 | 0.623 | 0.996 | 0.025 | 0.451 | 0.682 | 0.0001 | 0.044 | 0.555 |
Abbreviation: CTCs=circulating tumour cells.